Avalo (AVTX) CMO Doyle Mittie Exercises Options, Sells 1,000 Shares

What Happened
Doyle Mittie, Chief Medical Officer of Avalo Therapeutics (AVTX), exercised 1,000 stock options (strike/consideration $12.65) on July 27, 2026 (cost $12,650) and sold 1,000 resulting shares the same day in an open-market sale at $20.00 per share (proceeds $20,000). The reported activity shows the option exercise and an immediate sale — a common pattern where exercised shares are sold shortly after conversion.

Key Details

• Transaction date: 2026-07-27.
• Exercise: 1,000 shares via option exercise at $12.65/share (total $12,650).
• Sale: 1,000 shares sold at $20.00/share (total proceeds $20,000). Estimated gross gain before taxes/fees ≈ $7,350.
• A separate reporting line shows a derivative conversion/disposition of 1,000 at $0.00 consistent with the option being converted into shares.
• Trades were effected pursuant to a Rule 10b5-1 trading plan adopted November 13, 2025 (footnote).
• Vesting note: option vests 25% on July 15, 2025, remainder monthly over three years (footnote).
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Filing timeliness: Report filed 2026-07-29 for transactions on 2026-07-27 — appears timely (within required reporting window).

Context
This is effectively an exercise followed by an immediate sale (cashless-style outcome): the officer realized proceeds rather than holding newly acquired shares. The presence of a 10b5-1 plan indicates the sale was pre-arranged, which is common for insiders managing tax or liquidity needs and does not by itself signal a change in insider sentiment.